ANAB · NasdaqGS
Biotechnology · United States
Snapshot 2026-11-11 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Company websiteQ2 2026
Published 2026-09-21
Q2 2026 REPORT HIGHLIGHTS
Anaptys reported growing Jemperli royalties, a one-time tax-driven profit and an unresolved contract case; our HOLD values post-Sagard cash at $58 per share.
H1 Jemperli sales rose 30.3%, pushing Anaptys toward higher contractual tiers.
Q2 pretax loss became a large profit only after a $181.491M tax benefit.
About $302.5M had been earned; management estimates paydown in H2 2027.
Trial is complete, the October 20 hearing remains ahead and the remedy is unresolved.
Audited operating outflows total $52.559M, not the release's $72.9M sentence.
Comparable businesses
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.
| Metric | ANABAnaptysBio, Inc.Snapshot 2026-11-11Financial period: 2026-06-30 |
|---|---|
| Market capMarket value, converted to USD | US$1.46B |
| Forward P/EProvider forward earnings estimate | 10.75x |
| EV / EBITDAEnterprise value / trailing EBITDA | 23.61x |
| Revenue growthLatest quarter vs prior-year quarter | 23.5% |
| Operating marginLatest reported quarter | 61.9% |
| Free cash flow yieldTrailing cash flow / market cap | — |
| Net debt / EBITDANet debt / trailing EBITDA | 1.60x |
| Debt / equityTotal debt / positive book equity | 25.47x |
| Trailing P/ETrailing twelve-month earnings | — |
| Price / bookPrice / positive book equity per share | 136.99x |
| EV / salesEnterprise value / trailing revenue | 14.63x |
| Earnings growthLatest quarter vs prior-year quarter | — |
| Gross marginTrailing twelve months | 105.0% |
| Net marginTrailing twelve months | 247.0% |
| Return on equityProvider trailing return; positive equity only | — |
| Free cash flow marginTrailing free cash flow / revenue | — |
| Dividend yieldIndicated annual dividend / price | — |
| Earnings payoutProvider trailing dividend payout | 0.0% |
| Current ratioCurrent assets / current liabilities | 5.61x |
| BetaProvider historical market sensitivity | 0.37 |
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Price history loads separately.
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-11-11. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
FREE RESEARCH PACKET · Q2 2026
Anaptys reported growing Jemperli royalties, a one-time tax-driven profit and an unresolved contract case; our HOLD values post-Sagard cash at $58 per share.
Research published September 21, 2026 · Download original report
Read Research PacketPresentation · 2026-09-21 · YouTube
Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.
